On March 15, 2023 Veracyte, Inc. (Nasdaq: VCYT) reported that three abstracts highlighting the company’s unique, multi-omics capabilities and offerings for biopharmaceutical partners will be presented at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2023, taking place April 14-19, 2023, at the Orange County Convention Center in Orlando, Florida (Press release, Veracyte, MAR 15, 2023, View Source [SID1234628801]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Veracyte’s comprehensive multi-omics expertise and tools provide our biopharma partners with actionable insights to help them confidently advance every step of their oncology drug development programs," said Corinne Danan, general manager of Veracyte’s Biopharma business unit. "The abstracts accepted for presentation at AACR (Free AACR Whitepaper) 2023 will highlight new learnings and tools that demonstrate our ongoing commitment to continually enhancing and expanding the services available to these partners."

Following are details of the Veracyte abstracts that will be shared during poster sessions at the AACR (Free AACR Whitepaper) Annual Meeting 2023:

Title:

Deciphering the tumor microenvironment at single-cell resolution using a workflow combining RNA transcript and protein detection with Brightplex, a sequential chromogenic multiplex assay

Presenter:

Jacques Fieschi, Ph.D., Veracyte

Date/Time:

Tuesday, April 18, 1:30-5:00 p.m. ET

Location:

Poster Section 4

Poster #:

14

Abstract #:

4624

Title:

Veracyte Biopharma Atlas for colorectal cancer: combining multi-parameter approach and machine learning to capture the complexity of the tumor immune contexture.

Presenter:

Florence Monville, Ph.D., Research Discovery, Veracyte

Date/Time:

Tuesday, April 18, 1:30-5:00 p.m. ET

Location:

Poster Section 37

Poster #:

26

Abstract #:

5476

Title:

Defining the cancer Immunogram using multimodal analysis to guide immunotherapy in diffuse large B cell lymphoma

Presenter:

Régis Perbost, Ph.D., Veracyte and Mike Mattie, Ph.D., Kite a Gilead company

Date/Time:

Wednesday, April 19, 9:00 a.m.-12:30 p.m. ET

Location:

Poster Section 4

Poster #:

21

Abstract #:

5879

Veracyte will also host a Spotlight Theater at AACR (Free AACR Whitepaper) 2023, highlighting how insights from the company’s multi-omics offerings and analytical capabilities can help biopharma partners more confidently advance oncology drug development programs

Title:

Leveraging multi-omics insights to advance drug development programs

Speakers:

Corinne Danan, General Manager, Biopharma Services, Veracyte

Jacques Fieschi, Ph.D., Research Discovery, Veracyte

Jérôme Galon, Ph.D., Scientific Executive Director, Veracyte, and Research Director, Inserm

Date/Time:

Sunday, April 16, 3:30-4:30 p.m. ET

Location:

Exhibit Hall, Spotlight Theater

On March 15, 2023 Targovax ASA (OSE: TRVX) reported that an abstract describing its circular RNA platform has been accepted for poster presentation at the 2023 American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting in Orlando, USA (Press release, Targovax, MAR 15, 2023, View Source [SID1234628800]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The abstract describes the advantage of protein expression utilizing Targovax´proprietary circAde vector system. By comparing protein expression from circRNA and mRNA-based vectors, it is shown that the circAde-system out-performs conventional mRNA-based designs, both in terms of protein expression level and durability. Persistent and prolonged protein expression in patients is expected to result in positive treatment outcomes. The results thus highlight the circAde platform’s potential for development of novel, more effective medicines for the treatment of cancer and other diseases.

The abstract has been released on the AACR (Free AACR Whitepaper) website (View Source!/10828/presentation/5271). The poster is scheduled for presentation Tuesday 18 April 2023 and will be available on Targovax’s website after the presentation.

Poster title: circAde: a circRNA-based system for prolonged and more effective treatment of cancer
Date and time: Tuesday 18 April 2023, 13:30- 17:00 CDT / 20:30-24:00 CET
Location: Orange County Convention Center, Orlando, Florida
Session title: High-throughput Screening, Lead Identification and Optimization, and in Silico Drug Discovery
Poster number: 5335 / 17
Presenter: Thomas Birkballe Hansen, VP Research, Targovax
About AACR (Free AACR Whitepaper)

The AACR (Free AACR Whitepaper) Annual Meeting is the focal point of the cancer research community, where scientists, clinicians, other health care professionals, survivors, patients, and advocates gather to share the latest advances in cancer science and medicine. From population science and prevention; to cancer biology, translational, and clinical studies; to survivorship and advocacy; the AACR (Free AACR Whitepaper) Annual Meeting highlights the work of the best minds in cancer research from institutions all over the world.

For further information, please contact:
Erik Digman Wiklund, CEO
Phone: +47 413 33 536
Email: [email protected]

Renate Birkeli, Investor Relations
Phone: +47 922 61 624
Email: [email protected]

Media enquires:
Andreas Tinglum – Corporate Communications (Norway)
Phone: +47 9300 1773
Email: [email protected]

On March 15, 2023 Sysmex Corporation (HQ: Kobe, Japan; Chairman and CEO: Hisashi Ietsugu) reported that as of February 28, 2023, Sysmex has received approval for a partial change to its OncoGuide NCC Oncopanel System (the "System") for use as a companion diagnostic to futibatinib (generic name)1 for patients with biliary tract cancer (Press release, Sysmex, MAR 15, 2023, View Source [SID1234628799]).Futibatinib is a molecular-targeted agent currently under development by Taiho Pharmaceutical Co., Ltd. (HQ: Chiyoda-ku, Tokyo, Japan; President and Representative Director: Masayuki Kobayashi).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Biliary tract cancer is known to develop in approximately 26,000 patients annually in Japan,3 with a 5-year relative survival rate4 of less than 30%,5 and has the second poorest prognosis of any cancer after pancreatic cancer. At present, this disease has few treatment options, and no standard treatment has been sufficiently established for locally advanced or metastatic biliary tract cancer that has progressed after first-line treatment. Development is actively underway in pursuit of molecular-targeted therapeutic agents that target specific genetic abnormalities such as FGFR2 gene6 rearrangements, which are believed to be closely related to cancer cell survival and proliferation.

In 2018, Sysmex became the first manufacturer in Japan to receive manufacturing and marketing approval for a system for use in cancer genome profiling.7 The Company has since contributed to the promotion of cancer genomic medicine in Japan with a testing flow that can be conducted entirely in Japan, while promptly providing the testing to various medical institutions. Sysmex was working on the development of a companion diagnostic device aimed at commercialization, jointly with Taiho Pharmaceutical, which is developing futibatinib, an FGFR inhibitor for the treatment of previously treated locally advanced or metastatic biliary tract cancer harboring FGFR2 gene rearrangements, including gene fusions. On September 2, 2022, Sysmex applied for a partial change with an additional intended use for the System in Japan. Taiho Pharmaceutical applied for manufacturing and marketing approval for futibatinib in Japan on July 28, 2022.

Sysmex has received approval for a partial change to the System to include its use as a companion diagnostic for futibatinib for biliary tract cancer, in addition to cancer genome profiling. This approval will allow the System to be used to detect FGFR2 gene fusions by analyzing gene rearrangements, thereby assisting in identifying patients with biliary tract cancer who may be eligible for futibatinib. Sysmex will press forward with its efforts aimed at early insurance coverage and market introduction in Japan. If this test is available with insurance coverage in the future, it is expected to provide another treatment option for patients with locally advanced or metastatic biliary tract cancer.

Sysmex will continue to work on the early commercialization of high-value testing and diagnostic technologies to offer optimal treatment for each patient, while also contributing to the development and evolution of personalized medicine.

On March 15, 2023 Sporos BioDiscovery, Inc. (a wholly owned affiliate of Sporos Bioventures, "Sporos" or the "Company"), a precision oncology company developing a diversified pipeline of small molecule therapeutic programs targeting cancer vulnerabilities in the tumor and tumor microenvironment, reported that it will present a poster highlighting preclinical data from the company’s novel, isoform selective TEAD inhibitor, SPR1, at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2023 taking place April 14-19, 2023, in Orlando, FL (Press release, Sporos Bioventures, MAR 15, 2023, View Source [SID1234628798]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We look forward to presenting preclinical data on our TEAD inhibitor, which we believe has best-in-class potential based on its optimized TEAD isoform selectivity profile and resultant preclinical activity superior to that of other compounds in development," said Stephen Rubino, Ph.D., Sporos’ Chief Executive Officer. "SPR1 inhibitors show single-agent activity against multiple TEAD-dependent cell lines in vitro and in vivo, including a range of non-NF2 mutation cell lines and those cell lines that are simply YAP-hyperactive. In addition, our differentiated TEAD inhibitors have demonstrated potent synergistic activity in combination with inhibitors of the MAPK pathway, creating the potential for broad applicability across a number of cancers with serious unmet medical need."

Presentation Details:

Title: A next generation TEAD inhibitor with refined isoform specificity for superior safety & efficacy
Session Category: Experimental and Molecular Therapeutics
Session Title: New Drug Targets
Session Date and Time: Sunday Apr 16, 2023, 1:30 PM – 5:00 PM
Abstract Number: 445

On March 15, 2023 RS Research, a clinical-stage biotechnology start-up developing smart nanomedicines for targeted chemotherapy, reported the acceptance of a poster presentation at the European Society for Medical Oncology Targeted Anticancer Therapies (ESMO TAT) 2023 Congress on 6-8 March in Paris – France, being known as "The Home of Phase I in Oncology" (Press release, RS Research, MAR 15, 2023, View Source [SID1234628797]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

RS Research’s platform technology allows designing targeted drug candidates for different indications, which yields into development of the company’s own portfolio consisting of 5 drug candidates, as well as an important co-development potential. The nanocarriers introduce a versatile targeting capability and are suitable for loading a single or a combination of chemotherapeutic agents, with superior pharmacokinetic profiles while the targeting enables the drugs to accumulate in the tumor ensuring an enhanced therapeutic index and thus offering reduced toxicity profile.

RS-0139 is the lead candidate in Phase I clinical trial, aiming to deliver docetaxel specifically into integrin receptor expressing tumors such as NSCLC, breast, ovarian, prostate and pancreatic as well as head & neck carcinoma. RS Research Co-Founder and CSO Prof. Dr. Rana Sanyal and Medical Director Gülşah Nomak, MD presented the candidates’ promising preclinical data at ESMO (Free ESMO Whitepaper) TAT 2023.

Poster Title: RS-0139, a novel tumor-targeted delivery of docetaxel, with potent anti-tumor activity in a broad spectrum of tumor cell lines and xenograft models

Date: 6 March 2023

Location: Hall Bordeaux

Poster No: 100P

Presenter: Prof. Rana Sanyal, PhD; Co-Founder & CSO, RS Research | Gülşah Nomak, MD; Medical Director, RS Research

The poster abstract will be available online at the ESMO (Free ESMO Whitepaper) TAT 2023 website.